Nevertheless, Albert Bourla has been lobbying the U.S. government—as high as President Donald Trump himself—to skip the ...

Despite executing "perfectly," Octagon confronted a “scientific no-go,” CEO Isaac Stoner said in his LinkedIn post announcing ...

While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by ...

The condition, recessive dystrophic epidermolysis bullosa, causes chronic wounds and has an 84% mortality rate by age 40.

Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist ...

The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital ...

Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, ...

In a recent interview, FDA Commissioner Marty Makary said there “should be nothing political about the FDA.” Recent actions ...

Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...